1
|
Bramhall M, Rich K, Chakraborty A, Logunova L, Han N, Wilson J, McLaughlin J, Brass A, Cruickshank SM. Differential Expression of Soluble Receptor for Advanced Glycation End-products in Mice Susceptible or Resistant to Chronic Colitis. Inflamm Bowel Dis 2020; 26:360-368. [PMID: 31840738 PMCID: PMC7012299 DOI: 10.1093/ibd/izz311] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/10/2019] [Indexed: 12/12/2022]
Abstract
BACKGROUND Identifying the factors that contribute to chronicity in inflamed colitic tissue is not trivial. However, in mouse models of colitis, we can investigate at preclinical timepoints. We sought to validate murine Trichuris muris infection as a model for identification of factors that promote development of chronic colitis. METHODS We compared preclinical changes in mice with a resolving immune response to T. muris (resistant) vs mice that fail to expel the worms and develop chronic colitis (susceptible). Findings were then validated in healthy controls and patients with suspected or confirmed IBD. RESULTS The receptor for advanced glycation end products (RAGE) was highly dysregulated between resistant and susceptible mice before the onset of any pathological signs. Increased soluble RAGE (sRAGE) in the serum and feces of resistant mice correlated with reduced colitis scores. Mouse model findings were validated in a preliminary clinical study: fecal sRAGE was differentially expressed in patients with active IBD compared with IBD in remission, patients with IBD excluded, or healthy controls. CONCLUSIONS Preclinical changes in mouse models can identify early pathways in the development of chronic inflammation that human studies cannot. We identified the decoy receptor sRAGE as a potential mechanism for protection against chronic inflammation in colitis in mice and humans. We propose that the RAGE pathway is clinically relevant in the onset of chronic colitis and that further study of sRAGE in IBD may provide a novel diagnostic and therapeutic target.
Collapse
Affiliation(s)
- Michael Bramhall
- Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Victoria, Australia,Lydia Becker Institute of Immunology and Inflammation, Manchester Academic Health Science Centre, School of Biological Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, UK
| | - Kevin Rich
- Lydia Becker Institute of Immunology and Inflammation, Manchester Academic Health Science Centre, School of Biological Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, UK
| | - Ajanta Chakraborty
- Lydia Becker Institute of Immunology and Inflammation, Manchester Academic Health Science Centre, School of Biological Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, UK
| | - Larisa Logunova
- Lydia Becker Institute of Immunology and Inflammation, Manchester Academic Health Science Centre, School of Biological Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, UK
| | - Namshik Han
- Manchester Academic Health Science Centre, School of Medical Sciences, The University of Manchester, Manchester, UK,Milner Therapeutics Institute, University of Cambridge, Cambridge, UK
| | | | - John McLaughlin
- Salford Royal NHS Foundation Trust, Salford, UK,Division of Diabetes, Endocrinology and Gastroenterology, School of Medical Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, UK
| | - Andy Brass
- Manchester Academic Health Science Centre, School of Medical Sciences, The University of Manchester, Manchester, UK
| | - Sheena M Cruickshank
- Lydia Becker Institute of Immunology and Inflammation, Manchester Academic Health Science Centre, School of Biological Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, UK,Address correspondence to: S. M. Cruickshank, AV Hill Building, University of Manchester, Manchester M13 9PT, UK ()
| |
Collapse
|